- Home
- RAPP
as 09-12-2024 1:32pm EST
Stocks
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 743.6M | IPO Year: | 2024 |
| Target Price: | $35.00 | AVG Volume (30 days): | 95.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.55 - $28.08 | Next Earning Date: | 11-10-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rapport Therapeutics Inc. Common Stock (RAPP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HEALY JAMES | RAPP | Director | Jul 1 '24 | Buy | $24.59 | 44,032 | $1,079,575.36 | 28,993 |
Latest Rapport Therapeutics Inc. Common Stock News
RAPP Breaking Stock News: Dive into RAPP Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
GlobeNewswire
14 days ago
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
GlobeNewswire
a month ago
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
GlobeNewswire
a month ago
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
GlobeNewswire
3 months ago
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Compare RAPP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPP Rapport Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.